Adicet Bio, Inc (ACET)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Chen Schor
Employees:
90
500 BOYLSTON STREET, 12TH FLOOR, BOSTON, MA 02116
617-482-2333

Adicet Bio, Inc. discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. Lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 626.868 Million Shares Outstanding40.004 Million Avg 30-day Volume 294.308 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.01
Price to Revenue24.9407 Debt to Equity0.0 EBITDA-38.779 Million
Price to Book Value4.0656 Operating Margin-218.90740000000002 Enterprise Value351.9 Million
Current Ratio4.464 EPS Growth0.619 Quick Ratio4.209
1 Yr BETA 1.8853 52-week High/Low 21.17 / 6.25 Profit Margin-204.8707
Operating Cash Flow Growth-49.028 Altman Z-Score4.9826 Free Cash Flow to Firm -176.001 Million
View SEC Filings from ACET instead.

View recent insider trading info

Funds Holding ACET (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ACET

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-06-21:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-06-06:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-26:
    Item 7.01: Regulation FD Disclosure
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-05:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-04-19:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2022-03-24:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-03-15:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-10:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2021-12-06:
    Item 8.01: Other Events
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    15.3 Thousand total shares from 3 transactions

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    SCHOR CHEN PRESIDENT & CEO

    • Officer
    • Director
    197,553 2022-08-04 5

    HARVEY BRIAN NICHOLAS CHIEF FINANCIAL OFFICER

    • Officer
    65,912 2022-08-04 5

    HEALEY DON CHIEF TECHNOLOGY OFFICER

    • Officer
    63,401 2022-08-04 5

    GALIMI FRANCESCO SVP & CHIEF MEDICAL OFFICER

    • Officer
    70,384 2022-08-04 6

    AFTAB BLAKE CHIEF SCIENTIFIC OFFICER

    • Officer
    49,434 2022-08-04 11

    DUBIN STEVE

    • Director
    18,500 2022-06-02 1

    GORDON CARL L

    • Director
    18,500 2022-06-02 2

    KAUFFMAN MICHAEL

    • Director
    18,500 2022-06-02 3

    CHODAKEWITZ JEFFREY

    • Director
    18,500 2022-06-02 1

    SINCLAIR ANDREW

    • Director
    18,500 2022-06-02 3

    JAKOBOVITS AYA

    • Director
    18,500 2022-06-02 5

    SANNA BASTIANO

    • Director
    18,500 2022-06-02 1

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ORBIMED CAPITAL GP VI LLC

    ORBIMED GENESIS GP LLC

    ORBIMED ADVISORS ISRAEL II LTD

    ORBIMED ISRAEL GP II, L.P.

    ORBIMED ISRAEL GP LTD.

    ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

    • Director
    • 10% Owner
    638,942 2021-12-10 1

    ABBOT STEWART SEE REMARKS

    • Officer
    5,000 2021-06-11 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP V LLC

    ORBIMED CAPITAL GP VI LLC

    ORBIMED ADVISORS ISRAEL II LTD

    ORBIMED ISRAEL GP II, L.P.

    ORBIMED ISRAEL GP LTD.

    ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

    • Director
    • 10% Owner
    7,232,856 2021-02-12 1

    CHIMOVITS EREZ

    • Director
    • 10% Owner
    7,232,856 2021-02-12 0

    KLICKSTEIN LLOYD CHIEF INNOVATION OFFICER

    • Officer
    0 2021-02-12 0

    KREHLIK CARRIE CHIEF HUMAN RESOURCES OFFICER

    • Officer
    0 2021-02-12 0

    ORBIMED CAPITAL GP V LLC

    ORBIMED ADVISORS ISRAEL II LTD

    ORBIMED ISRAEL GP II, L.P.

    ORBIMED ISRAEL GP LTD.

    ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP

    • Director
    0 2020-09-15 0

    SCHINDEL YAIR CHAIM

    • Director
    0 2020-09-15 0

    SILVERSTEIN JONATHAN

    • Director
    0 2020-06-03 0

    FONTEYNE PAUL R.

    • Director
    0 2020-06-03 0

    SULLIVAN LYNNE MARIE

    • Director
    0 2020-06-03 0

    STEINBERG DAVID ADAM

    • Director
    0 2020-06-03 0

    GRISSINGER MICHAEL

    • Director
    0 2020-06-03 0

    PURETECH HEALTH LLC

    • 10% Owner
    2,119,696 2019-12-18 0

    MCCABE JOHN J VICE PRESIDENT, FINANCE

    • Officer
    12,867 2019-12-06 0

    MANNICK JOAN CHIEF MEDICAL OFFICER

    • Officer
    2,004,585 2019-12-06 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP VI LLC

    • Director
    • 10% Owner
    4,830,387 2018-01-30 1

    LEVIN ALAN G

    • Director
    3,164 2014-05-13 0

    ROSEN DAVID B. SR. V.P. - RISING PHARMA

    • Officer
    1,007,500 2012-02-17 0

    GUCCIONE SALVATORE J SR PRESIDENT AND COO

    • Officer
    • Director
    40,936 2012-02-16 0

    GOLD RONALD PRESIDENT & COO - RISING PHARM

    • Officer
    1,041,000 2011-11-29 0

    EILENDER ALBERT L CHAIRMAN & CHIEF EXEC. OFFICER

    • Officer
    • Director
    90,606 2011-11-25 0

    BRITTON WILLIAM N

    • Director
    11,746 2009-01-13 0

    ROTH DOUGLAS A CFO, SECRETARY, TREASURER

    • Officer
    13,521 2007-04-09 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    HEALEY DON - Officer CHIEF TECHNOLOGY OFFICER

    2022-08-08 20:26:23 -0400 2022-08-04 A 16,000 a 68,934 direct -3.7725 0.0 1 -3.7725 2

    HEALEY DON - Officer CHIEF TECHNOLOGY OFFICER

    2022-08-08 20:26:23 -0400 2022-08-04 F 5,533 $18.25 d 63,401 direct -3.7725 0.0 1 -3.7725 2

    HARVEY BRIAN NICHOLAS - Officer CHIEF FINANCIAL OFFICER

    2022-08-08 20:27:44 -0400 2022-08-04 A 16,000 a 70,608 direct -3.7725 0.0 1 -3.7725 2

    HARVEY BRIAN NICHOLAS - Officer CHIEF FINANCIAL OFFICER

    2022-08-08 20:27:44 -0400 2022-08-04 F 4,696 $18.25 d 65,912 direct -3.7725 0.0 1 -3.7725 2

    AFTAB BLAKE - Officer CHIEF SCIENTIFIC OFFICER

    2022-08-08 20:29:15 -0400 2022-08-04 A 16,000 a 54,967 direct -3.7725 0.0 1 -3.7725 2

    AFTAB BLAKE - Officer CHIEF SCIENTIFIC OFFICER

    2022-08-08 20:29:15 -0400 2022-08-04 F 5,533 $18.25 d 49,434 direct -3.7725 0.0 1 -3.7725 2

    GALIMI FRANCESCO - Officer SVP & CHIEF MEDICAL OFFICER

    2022-08-08 20:31:03 -0400 2022-08-04 A 16,000 a 75,917 direct -3.7725 0.0 1 -3.7725 2

    GALIMI FRANCESCO - Officer SVP & CHIEF MEDICAL OFFICER

    2022-08-08 20:31:03 -0400 2022-08-04 F 5,533 $18.25 d 70,384 direct -3.7725 0.0 1 -3.7725 2

    SCHOR CHEN - Director - Officer PRESIDENT & CEO

    2022-08-08 20:32:56 -0400 2022-08-04 A 48,000 a 144,000 direct -3.7725 0.0 1 -3.7725 2

    SCHOR CHEN - Director - Officer PRESIDENT & CEO

    2022-08-08 20:32:56 -0400 2022-08-04 F 21,288 $18.25 d 122,712 direct -3.7725 0.0 1 -3.7725 2

    AFTAB BLAKE - Officer CHIEF SCIENTIFIC OFFICER

    2022-08-05 18:43:54 -0400 2022-08-03 S 6,968 $18.00 d 38,967 direct yes -5.0689 0.0 1 -5.0689 2

    AFTAB BLAKE - Officer CHIEF SCIENTIFIC OFFICER

    2022-08-03 16:16:08 -0400 2022-08-01 S 6,968 $16.64 d 45,935 direct yes 2.6849 -14.137 2.6849 2 -14.137 6

    SCHOR CHEN - Director - Officer PRESIDENT & CEO

    2022-08-08 20:32:56 -0400 2022-07-06 G 53,424 d 96,000 direct -3.7725 0.0 1 -3.7725 2

    SCHOR CHEN - Director - Officer PRESIDENT & CEO see footnote

    2022-08-08 20:32:56 -0400 2022-07-06 G 53,424 a 143,260 indirect -3.7725 0.0 1 -3.7725 2

    AFTAB BLAKE - Officer CHIEF SCIENTIFIC OFFICER

    2022-07-07 17:12:16 -0400 2022-07-05 S 1,363 $14.50 d 52,903 direct yes -10.3226 -2.2043 0.0 1 -10.3226 2

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ADICET BIO INC ACET 2022-08-12 22:15:03 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 21:45:04 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 21:15:04 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 20:45:04 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 20:15:05 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 19:45:03 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 19:15:05 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 18:45:03 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 18:15:04 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 17:45:04 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 17:15:05 UTC 1.4496 0.8704 1000000
    ADICET BIO INC ACET 2022-08-12 16:45:04 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 16:15:04 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 15:45:04 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 15:15:05 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 14:45:04 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 14:15:05 UTC 1.4502 0.8698 1000000
    ADICET BIO INC ACET 2022-08-12 13:45:04 UTC 1.4569 0.8631 1000000
    ADICET BIO INC ACET 2022-08-12 13:15:04 UTC 1.4569 0.8631 1000000
    ADICET BIO INC ACET 2022-08-12 12:45:04 UTC 1.4569 0.8631 1000000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    Elevate your investments